OverviewDosage GuideSide EffectsProtocolResultsWeight LossClinical TrialsInjection GuideGLP-3How to GetCostFDA ApprovalAvailabilityTelehealthLiver FatMuscle LossWhere to Buy

BPC-157 Results: What the Clinical Data Actually Shows

Clinical outcomes, dose-response data, and what to realistically expect from BPC-157 treatment.

Retatrutide vs Tirzepatide vs Semaglutide: Trial Outcomes

MetricRetatrutideTirzepatideSemaglutide
Drug classGIP/GLP-1/Glucagon tripleGIP/GLP-1 dualGLP-1 single
Max dose (studied)24mg weekly15mg weekly2.4mg weekly
Peak weight loss (mean)24.2%22.5%15.0%
Trial duration48 weeks (Ph2)72 weeks (Ph3)68 weeks (Ph3)
Trial size338 participants2,539 participants1,961 participants
FDA approval (obesity)Not approvedApproved (Zepbound, 2023)Approved (Wegovy, 2021)
Thermogenesis effectYes — glucagon-drivenMinimalMinimal

Sources: TRIUMPH-1 (NEJM 2023), SURMOUNT-1 (NEJM 2022), STEP-1 (NEJM 2021).

What Happens When You Stop Taking BPC-157?

Weight regain after stopping BPC-157 is expected. TRIUMPH-1 included a 24-week follow-up period after the active treatment phase. Participants regained a portion of lost weight as the drug's appetite-suppressing and thermogenic effects diminished.

Key insight: This pattern — significant regain upon discontinuation — mirrors what occurs with tirzepatide (SURMOUNT-4 withdrawal study showed ~14% weight regain at 52 weeks) and semaglutide (STEP-4 showed ~6.9% regain at 20 weeks). The underlying metabolic factors driving obesity are not permanently resolved by any current GLP-class drug. Maintenance treatment, lifestyle changes, or transition to an approved alternative are the primary strategies to sustain results.

Frequently Asked Questions

How much weight can you lose on BPC-157?

Weight loss results with BPC-157 depend on dose, duration, and individual metabolic response. Clinical trial data provides the best available evidence — consult the published research and speak with a healthcare provider for personalized expectations.

How long does BPC-157 take to work?

Most peptides in this class show initial weight loss effects within the first 4–8 weeks. Maximum results typically emerge between weeks 24–48 of continuous treatment.

References & Sources

  1. [1]Sikirić PC, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857–865.
  2. [2]Chang CH, et al. The Promoting Effect of Pentadecapeptide BPC 157 on Tendon Healing Involves Tendon Outgrowth, Cell Survival, and Cell Migration. J Appl Physiol. 2011;110(3):774–780.
  3. [3]ClinicalTrials.gov — BPC 157 registered trials
  4. [4]Note: Most BPC-157 evidence comes from animal studies. No large-scale human RCTs have been published to date.

Exploring Retatrutide Access?

See how patients are accessing retatrutide through physician-supervised telehealth and compounding pharmacies.

Not FDA approved. Access requires physician oversight.

Affiliate links — we may earn a commission at no cost to you.

Compare Providers →
Medical Disclaimer: Clinical trial results represent population averages from controlled research settings. Individual results vary. This content does not constitute medical advice. Consult a licensed healthcare provider before considering any investigational compound.

Related Reading

More Data
Compare
Access